As previously demonstrated by our group, in order to optimize delivery and targeting of RNA-therapeutics to PDAC, we have encapsulated antimiRs and siRNA in tumor-penetrating nanocomplexes (TPNs) that have increase tumor targeting through sequential binding to integrins and NRP1 by tumor penetrating peptide iRGD [9, 10]. The gene discussed is NRP1; the disease is neoplasm.